Singapore: Research led by a Duke-NUS Graduate Medical School Singapore
(Duke-NUS) scientist has proved that certain special fats found in blood
are essential for human brain growth and function. Duke-NUS Associate Professor David Silver co-led two Nature Genetics
published studies which showed that mutations in the protein Mfsd2a
cause impaired brain development in humans. Mfsd2a is the transporter in
the brain for a special type of fat called lysophosphatidylcholines
(LPCs) - composed of essential fatty acids like omega-3. These studies
show, for the first time, the crucial role of these fats in human brain
growth and function.
In the first study, two families in Libya and Egypt with Mfsd2a
mutations were identified with severely reduced brain size, or
microcephaly. Their mutations eliminated Mfsd2a’s ability to transport
LPCs, which meant not enough LPCs were absorbed by the brain. In these
families, children affected by these mutations died between one and six
years of age. The study not only establishes a link between the
transport of LPCs by Mfsd2a and human brain growth and function, it is
also the first time a genetic disease has been related to LPC transport
in humans. The research was co-led by senior author Professor Joseph
Gleeson from Rockefeller University.
In a second, separate study, a family in North Pakistan was found to
have another type of mutation in the Mfsd2a gene which reduced its
transport activity. The individuals with this mutation also had
microcephaly, but in this case it was not lethal. However, they did have
intellectual disabilities, impaired control of their limbs, and absent
speech. Like the first study, findings are proof of the importance of
LPCs in brain development and function. The research was co-led by
senior author Professor Andrew H. Crosby from Exeter University.
In 2014, Dr. Silver published a landmark study in Nature which served
as a basis for these two studies. He and his team discovered that
Mfsd2a is the transporter for LPCs. Prior to this breakthrough, LPCs
were known to be found at high concentrations in our blood but their
function was a mystery. Dr. Silver’s team showed that mice genetically
engineered without Mfsd2a failed to transport LPCs into their brains -
which resulted in microcephaly. Since DHA deficiency in animals does not
result in microcephaly, this meant that LPCs are critical factors in
brain growth and function. Also, while it was previously believed the
brain made all the fat it needed, Dr. Silver’s research showed that LPCs
are transported there from the blood past the blood-brain barrier. His
work with Rockefeller and Exeter prove this in humans.
“Our work confirms the essential role of LPCs in brain development
and function in humans, and indicates that brain uptake of LPCs during
foetal development and in adult life is important,” said Dr. Silver,
co-lead on both studies, based in the Cardiovascular and Metabolic
Disorders Programme at Duke-NUS. “Now we are studying the functions of
LPCs in the brain, and the implications for application are very
exciting. We might be able to develop therapeutics in the future that
could prevent and treat neurological disorders, and improve brain growth
and function. We may even be able to target better brain nutrition for
babies, mothers, and the aged.”